Increased risks for suicide, self-harm, substance use, and psychiatric disorders in adults with inflammatory bowel disease: a nationwide study in the United States From 2007 to 2017 - Tse CS, Weng CH, Kwon M, Wolk CB, Brown LA, Malani K, Shah SA, Fine SD.
In an analysis of over 260 million emergency department visits across the United States from 2007 to 2017, inflammatory bowel disease conferred>10-fold risk for suicide deaths, self-harm, substance use, and psychiatric disorders, though the overall self-h... (Source: SafetyLit)
Source: SafetyLit - April 10, 2023 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
What People Who Have IBD Wish You Knew
Know someone with inflammatory bowel disease? They probably wish you knew a few things. WebMD explains. (Source: WebMD Health)
Source: WebMD Health - April 6, 2023 Category: Consumer Health News Source Type: news
What to Know About Pancreatic Disorders and IBD
Although inflammatory bowel disease (IBD) starts in the gut, it doesn’t always stay there. According to a 2015 study in the journal Inflammatory Bowel Disease, up to 47% of people with IBD will develop what are called “extraintestinal manifestations,” or EIMs. That means the disease ranges outside of the gut and causes problems in other tissues or organs. Not only are EIMs common, but many people experience more than one of them. That same 2015 study found that up to a quarter of IBD patients who develop an EIM will have more than one.
The skin, joints, and eyes are among the most common sites of these be...
Source: TIME: Health - April 5, 2023 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized Gut health Source Type: news
Forcing Canadians to switch from life-changing drugs saves governments millions. Do patients pay a price?
Ontario is the eighth Canadian jurisdiction to switch patients with Crohn's disease and other conditions from life-changing biologic drugs to more cost-effective 'biosimilars.' Both options are considered effective, and the swap saves millions. But should patients be forced to make the change? (Source: CBC | Health)
Source: CBC | Health - April 1, 2023 Category: Consumer Health News Tags: News/Health Source Type: news
Vedolizumab Aids Remission in Chronic Pouchitis After Ileal Pouch-Anal Anastomosis
FRIDAY, March 31, 2023 -- For patients with chronic pouchitis after undergoing restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) for ulcerative colitis, treatment with vedolizumab is more effective than placebo for inducing... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 31, 2023 Category: Pharmaceuticals Source Type: news
Vedolizumab Proves Its Worth in Treating Chronic Pouchitis
(MedPage Today) -- Vedolizumab (Entyvio) was more effective at inducing remission in patients with chronic pouchitis after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis compared with placebo, a randomized phase IV trial showed.
Among... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - March 29, 2023 Category: Gastroenterology Source Type: news
High EHR Burden for Some GI Providers High EHR Burden for Some GI Providers
EHR use may be particularly burdensome for physicians who specialize in inflammatory bowel disease or hepatology, as well as for nonphysician GI care providers.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 29, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
U.S. sues Walmart for firing deli worker with Crohn's disease
Walmart Inc has been sued by the U.S. Equal Employment Opportunity Commission (EEOC), which on Tuesday accused the largest U.S. retailer of illegally firing a North Carolina deli worker with Crohn's disease. The EEOC said Walmart violated the Americans with Disabilities Act by dismissing Adrian…#walmartinc #eeoc #northcarolina #crohn #walmart #adriantucker #charlotte #statesville #melindadugas #bentonville (Source: Reuters: Health)
Source: Reuters: Health - March 28, 2023 Category: Consumer Health News Source Type: news
Peninsula cell therapy company lands big deal with Regeneron
While most cell therapy companies target cancer, Sonoma Bio is hitting autoimmune and inflammatory diseases, including rheumatoid arthritis, ulcerative colitis and more. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 28, 2023 Category: American Health Authors: Ron Leuty Source Type: news
Ustekinumab Effectiveness and Safety in Ulcerative Colitis Ustekinumab Effectiveness and Safety in Ulcerative Colitis
Does the effectiveness and safety of ustekinumab seen in clinical trials translate to real-world clinical outcomes?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 23, 2023 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Episode 3: Pregnancy, Fertility, Ulcerative Colitis: Facts vs Fiction Episode 3: Pregnancy, Fertility, Ulcerative Colitis: Facts vs Fiction
Join Drs Sunanda Kane and Uma Mahadevan as they set out to separate fact from fiction when treating patients with ulcerative colitis before, during, and after pregnancy.Medscape (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - March 21, 2023 Category: Surgery Tags: Gastroenterology InDiscussion Source Type: news
Comparing Tofacitinib and Vedolizumab in Ulcerative Colitis Comparing Tofacitinib and Vedolizumab in Ulcerative Colitis
Which of these two drugs is the most effective option for ulcerative colitis patients who previously failed anti-TNF treatment?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 21, 2023 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
‘We’ll look back and say that this was a bargain.’ Takeda reveals first data from its $4 billion autoimmune disease pill
In an intermediate-stage clinical study of 259 people with moderate-to-severe plaque psoriasis, the highest dose of the daily pill completely cleared itchy and painful patches of skin in one-third of the patients after 12 weeks. “We’re offering the potential for a functional cure,” Andrew Plump,…#andrewplump #takeda #boston #nimbustherapeutics #neworleans #plump #crohns #nimbus #tyk2 #bristolmyerssquibb (Source: Reuters: Health)
Source: Reuters: Health - March 18, 2023 Category: Consumer Health News Source Type: news
Clinical Guideline Developed for Use of Biomarkers in Ulcerative Colitis
FRIDAY, March 17, 2023 -- In a clinical practice guideline issued by the American Gastroenterological Association and published in the March issue of Gastroenterology, recommendations are presented for the role of biomarkers in the management of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 17, 2023 Category: Pharmaceuticals Source Type: news
TREMFYA ® (guselkumab) Real-World Data Analyses Show Greater Treatment Persistence Than IL-17s in Both Bio-naïve and Bio-experienced Patients Living With Moderate to Severe Plaque Psoriasis
SPRING HOUSE, PENNSYLVANIA, March 17, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data, showing that initiation of TREMFYA® (guselkumab) was associated with greater treatment persistencea compared to secukinumab or ixekizumab in bio-naïve and bio-experienced patientsb living with moderate to severe plaque psoriasis (PsO), based on pairwise analysesc of real-world data.[1],[2] Additionally, in a post-hoc analysis of Phase 3 VOYAGE 2 clinical trial results, TREMFYA demonstrated durable clinical efficacy, itch relief and quality-of-life improvements in patients living with scal...
Source: Johnson and Johnson - March 17, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
